Jaume Bordas-Martinez

@fphag.org

Pulmonology
Hospital General de Granollers



                 

https://researchid.co/bordas-martinez

RESEARCH, TEACHING, or OTHER INTERESTS

Pulmonary and Respiratory Medicine

16

Scopus Publications

208

Scholar Citations

6

Scholar h-index

5

Scholar i10-index

Scopus Publications

  • Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF
    Jaume Bordas-Martinez, Neus Salord, Vanesa Vicens-Zygmunt, João Carmezim, Sandra Pérez, Eliseo Prado, María Calvo, Rosana Blavia, Guadalupe Bermudo, Salud Santos,et al.
    Springer Science and Business Media LLC
    Abstract Introduction Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. We assessed at one year: (1) the effect of CPAP and/or nocturnal oxygen therapy on IPF regarding lung function, blood mediators, and quality of life; (2) adherence to SDB treatment and SDB changes. Methodology This is a prospective study of consecutive newly diagnosed IPF patients initiating anti-fibrotic treatment. Lung function, polysomnography, blood tests and quality of life questionnaires were performed at inclusion and after one year. Patients were classified as obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and sleep-sustained hypoxemia (SSH). SDB therapy (CPAP and/or nocturnal oxygen therapy) was initiated if needed. Results Fifty patients were enrolled (36% had OSA, 22% CSA, and 12% SSH). CPAP was started in 54% of patients and nocturnal oxygen therapy in 16%. At one-year, polysomnography found improved parameters, though 17% of patients had to add nocturnal oxygen therapy or CPAP, while 33% presented SDB onset at this second polysomnography. CPAP compliance at one year was 6.74 h/night (SD 0.74). After one year, matrix metalloproteinase-1 decreased in OSA and CSA (p = 0.029; p = 0.027), C-reactive protein in OSA (p = 0.045), and surfactant protein D in CSA group (p = 0.074). There was no significant change in lung function. Conclusions Treatment of SBD with CPAP and NOT can be well tolerated with a high compliance. IPF patients may exhibit SDB progression and require periodic re-assessment. Further studies to evaluate the impact of SDB treatment on lung function and serological mediators are needed.

  • Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study
    Esteban Cano-Jiménez, Ana Villar Gómez, Eduardo Velez Segovia, Myriam Aburto Barrenechea, Jacobo Sellarés Torres, Joel Francesqui, Karina Portillo Carroz, Alan Jhunior Solis Solis, Orlando Acosta Fernández, Ana Belén Llanos González,et al.
    European Respiratory Society (ERS)
    BackgroundFibrotic hypersensitivity pneumonitis (fHP) is an immune-mediated interstitial lung disease caused by sensitisation to chronic allergen inhalation. This study aimed to determine prognostic indicators of progression and mortality in fHP.MethodsThis was a retrospective, multicentre, observational, cross-sectional cohort study of consecutive patients diagnosed with fHP from 1 January 2012 to 31 December 2021. Multivariate Cox regression analyses were used to calculate hazard ratios (HRs) with 95% confidence intervals for predictors of progression and survival.ResultsA total of 403 patients were diagnosed with fHP: median (interquartile range) age 66.5 (14.0) years, 51.9% females and 55.1% never-smokers. The cause of fHP was mainly fungal (39.7%) or avian (41.4%). Lung biopsy was performed in 269 cases (66.7%). In the whole cohort the variables that were related to mortality or lung transplant were older age (HR 1.08; p<0.001), percentage predicted forced vital capacity (HR 0.96; p=0.001), lymphocytosis in bronchoalveolar lavage (BAL) (HR 0.93; p=0.001), presence of acute exacerbation during follow-up (HR 3.04; p=0.001) and GAP (gender, age and lung physiology) index (HR 1.96; p<0.01). In the group of biopsied patients, the presence of fibroblastic foci at biopsy (HR 8.39; p<0.001) stands out in multivariate Cox regression analyses as a highly significant predictor for increased mortality or lung transplant. GAP index (HR 1.26; p=0.009), lymphocytosis in BAL (HR 0.97; p=0.018) and age (HR 1.03; p=0.018) are also predictors of progression.ConclusionsThe study identified several prognostic factors for progression and/or survival in fHP. The presence of fibroblastic foci at biopsy was a consistent predictor for increased mortality and the presence of lymphocytosis in BAL was inversely related to mortality.

  • Characterization of Sleep-Disordered Breathing in Idiopathic Pulmonary Fibrosis
    Jaume Bordas-Martinez, Neus Salord, Vanesa Vicens-Zygmunt, Sandra Pérez, Eliseo Prado, María Calvo, Rosana Blavia, Guadalupe Bermudo, Ana Montes-Worboys, Salud Santos,et al.
    Elsevier BV

  • Characteristics of long-COVID among older adults: a cross-sectional study
    Vered Daitch, Dana Yelin, Muhammad Awwad, Giovanni Guaraldi, Jovana Milić, Cristina Mussini, Marco Falcone, Giusy Tiseo, Laura Carrozzi, Francesco Pistelli,et al.
    Elsevier BV

  • Telemedicine home CPAP titration and follow-up in the COVID-19 scenario
    Jaume Bordas-Martinez, Neus Salord, Eva Fontanilles, Eliseo Prado, María Calvo, João Carmezim, Salud Santos, and Carmen Monasterio
    European Respiratory Society (ERS)
    IntroductionContinuous positive airway pressure (CPAP) titration was dramatically affected by the coronavirus disease 2019 (COVID-19) pandemic due to increased biological risk. This study aimed to compare successful CPAP adaptation and compliance with home telemedicine CPAP titration with the usual method based on face-to-face visits.MethodologyA prospective cohort using telemedicine home CPAP titration and follow-up during the COVID-19 pandemic (TC) was compared with a retrospective cohort receiving face-to-face pre-pandemic home titration (RC). The TC included a subgroup with a smartphone application (TC-APP). Successful CPAP adaptation and compliance at 1 month of follow-up were the main endpoints, while patient satisfaction and costs were secondary endpoints.Results210 consecutive patients were evaluated (80 RC and 130 TC). 36 patients were in the TC-APP subgroup. CPAP titration was successful in 90% in RCversus95% in TC and 100% in TC-APP. No compliance differences between groups were found at 1  month (4.79 h·night−1RC, 4.33  h·night−1TC and 4.59 h·night−1TC-APP). Mean±sdpatient satisfaction out of 10 was 7.69±2.05 in RCversus9.02±0.64 in TC (p<0.001). 64% of the TC-APP subgroup reported that their telemedicine strategy influenced an increase in CPAP use (p=0.011). CPAP adaptation with follow-up had an estimated direct staff cost per patient of EUR 19.61±8.61 in TC with no smartphone application usedversusEUR 23.79±9.94 in TC-APP (p=0.048).ConclusionsTelemedicine in CPAP titration and early follow-up is equivalent to the usual care in terms of successful adaptation and compliance, while achieving greater patient satisfaction.

  • Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program
    Jaume Bordas-Martinez, Lluís Matéu Gómez, David Cámara Menoyo, Marta López-Sánchez, Salud Santos, Maria Molina-Molina, and Rosa Planas
    Ovid Technologies (Wolters Kluwer Health)
    Telemedicine is proving to be a useful tool in the telemonitoring of respiratory patients and telerehabilitation programs. The use of telemedicine has been proposed by the main medical societies because of the limited resources and the healthcare workers infection risk in the Coronavirus Disease 2019 (COVID-19) pandemic. The aim of this pilot program is to evaluate the feasibility of COVID-19 telerehabilitation program from the hospital to the home with clinical, functional and patient satisfaction outcomes. Rehabilitation was initiated in the hospital by a physiotherapist and complemented by “Estoi” (a mobile application), which was continued at home with telemonitoring and messaging with the medical team. Patients’ habitual use of smartphones was not queried for inclusion. Sixteen patients were consecutively enrolled, 47% women with a mean age of 63 years old. 50% of patients completed ≥15 rehabilitation sessions. In total, 88% of patients referred that the mobile application incentive them to do more physical therapy, and 63% would choose telerehabilitation instead of center-based rehabilitation for new rehabilitation programs. Patient satisfaction (0–10) for the mobile application was 8.4 and 8.9 for the telerehabilitation program. Beginning telerehabilitation in the hospital could increase the efficacy and efficiency of physical therapy, which is safe for patients and healthcare workers. Following at home, this telerehabilitation program seems to encourage and empower patients who have reported high satisfaction. Further randomized studies with larger numbers of patients and multicenter studies are required to evaluate these results.

  • Radio-Histological Correlation of Lung Features in Severe COVID-19 Through CT-Scan and Lung Ultrasound Evaluation
    Pere Trias-Sabrià, Eduard Dorca Duch, Maria Molina-Molina, Samantha Aso, Marta Díez-Ferrer, Alfredo Marín Muñiz, Jaume Bordas-Martínez, Joan Sabater, Patricio Luburich, Belén del Rio,et al.
    Frontiers Media SA
    BackgroundPatients with coronavirus disease 2019 (COVID-19) can develop severe bilateral pneumonia leading to respiratory failure. Lung histological samples were scarce due to the high risk of contamination during autopsies. We aimed to correlate histological COVID-19 features with radiological findings through lung ultrasound (LU)-guided postmortem core needle biopsies (CNBs) and computerized tomography (CT) scans.MethodologyWe performed an observational prospective study, including 30 consecutive patients with severe COVID-19. The thorax was divided into 12 explorations regions to correlate LU and CT-scan features. Histological findings were also related to radiological features through CNBs.ResultsMean age was 62.56 ± 13.27 years old, with 96.7% male patients. Postmortem LU-guided CNBs were performed in 13 patients. Thirty patients were evaluated with both thoracic LU and chest CT scan, representing a total of 279 thoracic regions explored. The most frequent LU finding was B2-lines (49.1%). The most CT-scan finding was ground-glass opacity (GGO, 29%). Pathological CT-scan findings were commonly observed when B2-lines or C-lines were identified through LU (positive predictive value, PPV, 87.1%). Twenty-five postmortem echo-guided histological samples were obtained from 12 patients. Histological samples showed diffuse alveolar damage (DAD) (75%) and chronic interstitial inflammation (25%). The observed DAD was heterogeneous, showing multiple evolving patterns of damage, including exudative (33.3%), fibrotic (33.3%), and organizing (8.3%) phases. In those patients with acute or exudative pattern, two lesions were distinguished: classic hyaline membrane; fibrin “plug” in alveolar space (acute fibrinous organizing pneumonia, AFOP). C-profile was described in 33.3% and presented histological signs of DAD and lung fibrosis. The predominant findings were collagen deposition (50%) and AFOP (50%). B2-lines were identified in 66.7%; the presence of hyaline membrane was the predominant finding (37.5%), then organizing pneumonia (12.5%) and fibrosis (37.5%). No A-lines or B1-lines were observed in these patients.ConclusionLU B2-lines and C-profile are predominantly identified in patients with severe COVID-19 with respiratory worsening, which correspond to different CT patterns and histological findings of DAD and lung fibrosis.

  • Effects of Early Physical Therapy and Follow-Up in Acute Severe Coronavirus Disease 2019 Pneumonia: A Retrospective Observational Study
    Jaume Bordas-Martínez, Ana Luzardo-González, Alejandro Arencibia, Franco Tormo, Lluís Matéu, Vanesa Vicens-Zygmunt, Guadalupe Bermudo, Salud Santos, María Molina-Molina, Rosa Planas,et al.
    Frontiers Media SA
    BackgroundRehabilitation in subjects with severe coronavirus disease 2019 (COVID-19) pneumonia has been widely recommended. However, data regarding the starting time of rehabilitation, subjects and healthcare workers’ safety, as well as rehabilitation program features are limited. We aimed to assess the safety and characterize the effect of early and non-early physiotherapy on severe COVID-19 pneumonia subjects.MethodsA retrospective cohort study, including a consecutive sample of surviving subjects admitted to an acute care hospital due to severe COVID-19 pneumonia from March 13th to May 15th of 2020, is made. Subjects were separated into three groups: non-physical therapy, early physiotherapy (onset <7 days of admission), and non-early physiotherapy. Subject and therapist safety and length of hospital stay were the main evaluated outcomes.ResultsA total of 159 subjects were included (72% men; median age 62 years). Rehabilitation was performed on 108 subjects (32 early and 76 non-early physiotherapies). The length of hospital stay was 19 [interquartile range (IQR) 36.25] and 34 days (IQR 27.25) (p = 0.001) for early and non-early physiotherapy groups, respectively. No physiotherapist was infected and no subject adverse effect was identified. Multivariate analysis of subjects receiving physiotherapy during admission identified obesity [odds ratio (OR) 3.21; p-value 0.028], invasive mechanical ventilation (OR 6.25; p-value <0.001), and non-early physiotherapy (OR 3.54; p-value 0.017) as independent factors associated with a higher risk of prolonged hospital stay. Survivors’ follow-up after hospital discharge at 8 weeks was completed by 54% of subjects.ConclusionRehabilitation in acute severe COVID-19 pneumonia is safe for subjects and healthcare workers and could reduce the length of hospitalization stay, especially in those that may start early.

  • Multiple Solid Nodules at Post-COVID-19 Follow-up After Mild Pneumonia
    Jaume Bordas-Martinez, Belén del Río, and Maria Molina-Molina
    Elsevier BV

  • Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study
    Dana Yelin, Ili Margalit, Mayssam Nehme, Jaume Bordas-Martínez, Francesco Pistelli, Dafna Yahav, Idris Guessous, Xavier Durà-Miralles, Laura Carrozzi, Irit Shapira-Lichter,et al.
    MDPI AG
    Background: Long COVID has become a burden on healthcare systems worldwide. Research into the etiology and risk factors has been impeded by observing all diverse manifestations as part of a single entity. We aimed to determine patterns of symptoms in convalescing COVID-19 patients. Methods: Symptomatic patients were recruited from four countries. Data were collected regarding demographics, comorbidities, acute disease and persistent symptoms. Factor analysis was performed to elucidate symptom patterns. Associations of the patterns with patients’ characteristics, features of acute disease and effect on daily life were sought. Results: We included 1027 symptomatic post-COVID individuals in the analysis. The majority of participants were graded as having a non-severe acute COVID-19 (N = 763, 74.3%). We identified six patterns of symptoms: cognitive, pain-syndrome, pulmonary, cardiac, anosmia-dysgeusia and headache. The cognitive pattern was the major symptoms pattern, explaining 26.2% of the variance; the other patterns each explained 6.5–9.5% of the variance. The cognitive pattern was higher in patients who were outpatients during the acute disease. The pain-syndrome pattern was associated with acute disease severity, higher in women and increased with age. The pulmonary pattern was associated with prior lung disease and severe acute disease. Only two of the patterns (cognitive and cardiac) were associated with failure to return to pre-COVID occupational and physical activity status. Conclusion: Long COVID diverse symptoms can be grouped into six unique patterns. Using these patterns in future research may improve our understanding of pathophysiology and risk factors of persistent COVID, provide homogenous terminology for clinical research, and direct therapeutic interventions.

  • Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis
    Carmen Herranz, Francesca Mateo, Alexandra Baiges, Gorka Ruiz de Garibay, Alexandra Junza, Simon R Johnson, Suzanne Miller, Nadia García, Jordi Capellades, Antonio Gómez,et al.
    Springer Science and Business Media LLC
    Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis and monitoring can also be challenging due to the heterogeneity of symptoms and insufficiency of non‐invasive tests. Here, we propose monoamine‐derived biomarkers that provide preclinical evidence for novel therapeutic approaches. The major histamine‐derived metabolite methylimidazoleacetic acid (MIAA) is relatively more abundant in LAM plasma, and MIAA values are independent of VEGF‐D. Higher levels of histamine are associated with poorer lung function and greater disease burden. Molecular and cellular analyses, and metabolic profiling confirmed active histamine signaling and metabolism. LAM tumorigenesis is reduced using approved drugs targeting monoamine oxidases A/B (clorgyline and rasagiline) or histamine H1 receptor (loratadine), and loratadine synergizes with rapamycin. Depletion of Maoa or Hrh1 expression, and administration of an L‐histidine analog, or a low L‐histidine diet, also reduce LAM tumorigenesis. These findings extend our knowledge of LAM biology and suggest possible ways of improving disease management.

  • N3 hilar sampling decision in the staging of mediastinal lung cancer
    Jaume Bordas-Martinez, Jose Luis Vercher-Conejero, Guillermo Rodriguez-González, Noelia Cubero, Rosa M. Lopez-Lisbona, Marta Diez-Ferrer, Rachid Tazi, and Antoni Rosell
    European Respiratory Society (ERS)
    The guidelines [1–4] on invasive staging for lung cancer recommend endoscopic ultrasound-guided fine-needle aspiration over surgical staging in patients with a high suspicion of lymph node involvement, either by morphological criteria (>1 cm in short axis) on computed tomography (CT) or metabolic criteria on positron emission tomography (PET) uptake (standardised uptake value maximum (SUVmax) >2.5). This recommendation is also valid for a CT and PET negative mediastinum if there is a central tumour, N1 disease, a low uptake tumour or a T2 tumour (>3 cm). There is insufficient evidence for the sampling of morphometabolically normal N3 hilar lymph nodes https://bit.ly/3gWcar7

  • Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
    Jaume Bordas-Martínez, Ricard Gavaldà, Jessica G. Shull, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Guadalupe Bermudo-Peloche, Salud Santos, Neus Salord, Carmen Monasterio, Maria Molina-Molina,et al.
    European Respiratory Society (ERS)
    IntroductionIdiopathic pulmonary fibrosis (IPF) prognosis is heterogeneous despite antifibrotic treatment. Cluster analysis has proven to be a useful tool in identifying interstitial lung disease phenotypes, which has yet to be performed in IPF. The aim of this study is to identify phenotypes of IPF with different prognoses and requirements.MethodsObservational retrospective study including 136 IPF patients receiving antifibrotic treatment between 2012 and 2018. Six patients were excluded due to follow-up in other centres. Cluster analysis of 30 variables was performed using approximate singular value-based tensor decomposition method and comparative statistical analysis.ResultsThe cluster analysis identified three different groups of patients according to disease behaviour and clinical features, including mortality, lung transplant and progression-free survival time after 3-year follow-up. Cluster 1 (n=60) was significantly associated (p=0.02) with higher mortality. Diagnostic delay was the most relevant characteristic of this cluster, as 48% of patients had ≥2 years from first respiratory symptoms to antifibrotic treatment initiation. Cluster 2 (n=22) had the longest progression-free survival time and was correlated to subclinical patients evaluated in the context of incidental findings or familial screening. Cluster 3 (n=48) showed the highest percentage of disease progression without cluster 1 mortality, with metabolic syndrome and cardiovascular comorbidities as the main characteristics.ConclusionThis cluster analysis of IPF patients suggests that diagnostic and treatment delay are the most significant factors associated with mortality, while IPF progression was more related to metabolic syndrome and cardiovascular comorbidities.

  • Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers
    Jessica Germaine Shull, Maria Teresa Pay, Carla Lara Compte, Miriam Olid, Guadalupe Bermudo, Karina Portillo, Jacobo Sellarés, Eva Balcells, Vanesa Vicens‐Zygmunt, Lurdes Planas‐Cerezales,et al.
    Wiley
    ABSTRACTBackground and objectiveThe relationship between IPF development and environmental factors has not been completely elucidated. Analysing geographic regions of idiopathic pulmonary fibrosis (IPF) cases could help identify those areas with higher aggregation and investigate potential triggers. We hypothesize that cross‐analysing location of IPF cases and areas of consistently high air pollution concentration could lead to recognition of environmental risk factors for IPF development.MethodsThis retrospective study analysed epidemiological and clinical data from 503 patients registered in the Observatory IPF.cat from January 2017 to June 2019. Incident and prevalent IPF cases from the Catalan region of Spain were graphed based on their postal address. We generated maps of the most relevant air pollutant PM2.5 from the last 10 years using data from the CALIOPE air quality forecast system and observational data.ResultsIn 2018, the prevalence of IPF differed across provinces; from 8.1 cases per 100 000 habitants in Barcelona to 2.0 cases per 100 000 in Girona. The ratio of IPF was higher in some areas. Mapping PM2.5 levels illustrated that certain areas with more industry, traffic and shipping maintained markedly higher PM2.5 concentrations. Most of these locations correlated with higher aggregation of IPF cases. Compared with other risk factors, PM2.5 exposure was the most frequent.ConclusionIn this retrospective study, prevalence of IPF is higher in areas of elevated PM2.5 concentration. Prospective studies with targeted pollution mapping need to be done in specific geographies to compile a broader profile of environmental factors involved in the development of pulmonary fibrosis.

  • Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
    Jaume Bordas-Martinez, Ana Belén Llanos-González, Ramon Jodar-Masanes, Vanesa Vicens-Zygmunt, Guadalupe Bermudo, Patricio Luburich, Jordi Dorca, Maria Molina-Molina, and Guillermo Suarez-Cuartin
    Elsevier BV

  • Organizing pneumonia in a patient with hodgkin's lymphoma and large B cell lymphoma: a rare association
    Jaume Bordas-Martinez, Mercè Gasa, Eva Domingo-Domènech, and Vanesa Vicens-Zygmunt
    Elsevier BV

RECENT SCHOLAR PUBLICATIONS

  • Mediastinal staging lymph node probability map in non-small cell lung cancer
    J Bordas-Martinez, JL Vercher-Conejero, G Rodriguez-Gonzlez, ...
    Respiratory Research 26 (1), 113 2025

  • Impacto clnico y biolgico de los trastornos respiratorios del sueo en la fibrosis pulmonar idioptica
    J Bordas Martnez
    Universitat de Barcelona 2024

  • Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF
    J Bordas-Martinez, N Salord, V Vicens-Zygmunt, J Carmezim, S Prez, ...
    Respiratory Research 25 (1), 247 2024

  • Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study
    E Cano-Jimnez, AV Gmez, EV Segovia, MA Barrenechea, JS Torres, ...
    ERJ Open Research 10 (1) 2024

  • Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review
    J Bordas-Martinez, JR Miedema, BJ Mathot, L Seghers, RJH Galjaard, ...
    JHLT Open 3, 100054 2024

  • Characterization of sleep-disordered breathing in idiopathic pulmonary fibrosis
    J Bordas-Martinez, N Salord, V Vicens-Zygmunt, S Prez, E Prado, ...
    Archivos de bronconeumologia 59 (11), 768-771 2023

  • Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
    R Mndez, P Gonzlez-Jimnez, A Latorre, N Mengot, R Zalacain, ...
    Frontiers in Medicine 10, 1236142 2023

  • SAFETY PROFILE OF PIRFENIDONE IN COVID19 RESPIRATORY DISTRESS SYNDROME
    M Hernandez Argudo, G Bermudo Peloche, M Molina Molina, ...
    EUROPEAN RESPIRATORY JOURNAL 62 2023

  • Real-world of Nintedanib in a Spanish non-IPF progressive pulmonary fibrosis cohort
    V Vicens Zygmunt, J Bordas-Martinez, M Munoz-Bolano, ...
    EUROPEAN RESPIRATORY JOURNAL 62 2023

  • Physical exercise in post-COVID patients
    J Bordas Martinez, P Carrasco, M Berga, F Lopez, H Sanchis-Gilabert, ...
    EUROPEAN RESPIRATORY JOURNAL 62 2023

  • Relevance of the systematic sleep study on idiopathic pulmonary fibrosis (IPF)
    J Bordas Martinez, N Salord Oleo, V Vicens Zygmunt, R Blavia Aloy, ...
    EUROPEAN RESPIRATORY JOURNAL 62 2023

  • The extent of emphysema plays a role in morbidity-mortality in patients with CPFE and IPF
    F Gozzi, J Bordas-Martnez, N Santos-Erice, G Bermudo-Peloche, ...
    European Respiratory Journal 62 (suppl 67) 2023

  • (1248) Outcomes of Lung Transplantation in Patients with Hereditary Pulmonary Fibrosis-A Systematic Review
    J Bordas-Martinez, JR Miedema, RA Hoek, RH Galjaard, MH Raaijmakers, ...
    The Journal of Heart and Lung Transplantation 42 (4), S533 2023

  • Pirfenidone in post-covid19 pulmonary fibrosis (FIBRO-COVID): Phase-II randomized clinical trial (NCT04607928)
    GB Peloche, B Del Ro, V Vicens-Zygmunt, C Valenzuela, R Laporta, ...
    European Respiratory Journal 62 (suppl 67) 2023

  • Characteristics of long-COVID among older adults: a cross-sectional study
    V Daitch, D Yelin, M Awwad, G Guaraldi, J Milić, C Mussini, M Falcone, ...
    International journal of infectious diseases 125, 287-293 2022

  • Telemedicine home CPAP titration and follow-up in the COVID-19 scenario
    J Bordas-Martinez, N Salord, E Fontanilles, E Prado, M Calvo, ...
    ERJ Open Research 8 (4) 2022

  • Clinical and biological impact of respiratory sleep disorders in IPF
    J Bordas Martinez, N Salord, V Vicens Zygmunt, R Blavia Aloy, ...
    EUROPEAN RESPIRATORY JOURNAL 60 2022

  • Effects of early physical therapy in acute severe COVID-19 pneumonia
    J Bordas Martinez, M Hernandez Argudo, A Luzardo-Gonzalez, ...
    EUROPEAN RESPIRATORY JOURNAL 60 2022

  • Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program
    J Bordas-Martinez, LM Gmez, DC Menoyo, M Lpez-Snchez, S Santos, ...
    Medicine 101 (31), e29639 2022

  • Radio-histological correlation of lung features in severe COVID-19 through CT-scan and lung ultrasound evaluation
    P Trias-Sabri, E Dorca Duch, M Molina-Molina, S Aso, M Dez-Ferrer, ...
    Frontiers in Medicine 9, 820661 2022

MOST CITED SCHOLAR PUBLICATIONS

  • Characteristics of long-COVID among older adults: a cross-sectional study
    V Daitch, D Yelin, M Awwad, G Guaraldi, J Milić, C Mussini, M Falcone, ...
    International journal of infectious diseases 125, 287-293 2022
    Citations: 65

  • Patterns of long COVID symptoms: A multi-center cross sectional study
    D Yelin, I Margalit, M Nehme, J Bordas-Martnez, F Pistelli, D Yahav, ...
    Journal of Clinical Medicine 11 (4), 898 2022
    Citations: 56

  • Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers
    JG Shull, MT Pay, C Lara Compte, M Olid, G Bermudo, K Portillo, ...
    Respirology 26 (4), 352-359 2021
    Citations: 25

  • Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis
    C Herranz, F Mateo, A Baiges, G Ruiz de Garibay, A Junza, SR Johnson, ...
    EMBO Molecular Medicine 13 (9), e13929 2021
    Citations: 11

  • Effects of early physical therapy and follow-up in acute severe coronavirus disease 2019 pneumonia: A retrospective observational study
    J Bordas-Martnez, A Luzardo-Gonzlez, A Arencibia, F Tormo, L Matu, ...
    Frontiers in Medicine 9, 866055 2022
    Citations: 10

  • Radio-histological correlation of lung features in severe COVID-19 through CT-scan and lung ultrasound evaluation
    P Trias-Sabri, E Dorca Duch, M Molina-Molina, S Aso, M Dez-Ferrer, ...
    Frontiers in Medicine 9, 820661 2022
    Citations: 9

  • Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
    J Bordas-Martnez, R Gavald, JG Shull, V Vicens-Zygmunt, ...
    ERJ Open Research 7 (2) 2021
    Citations: 5

  • Characterization of sleep-disordered breathing in idiopathic pulmonary fibrosis
    J Bordas-Martinez, N Salord, V Vicens-Zygmunt, S Prez, E Prado, ...
    Archivos de bronconeumologia 59 (11), 768-771 2023
    Citations: 4

  • Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program
    J Bordas-Martinez, LM Gmez, DC Menoyo, M Lpez-Snchez, S Santos, ...
    Medicine 101 (31), e29639 2022
    Citations: 4

  • Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study
    E Cano-Jimnez, AV Gmez, EV Segovia, MA Barrenechea, JS Torres, ...
    ERJ Open Research 10 (1) 2024
    Citations: 3

  • Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
    R Mndez, P Gonzlez-Jimnez, A Latorre, N Mengot, R Zalacain, ...
    Frontiers in Medicine 10, 1236142 2023
    Citations: 3

  • Telemedicine home CPAP titration and follow-up in the COVID-19 scenario
    J Bordas-Martinez, N Salord, E Fontanilles, E Prado, M Calvo, ...
    ERJ Open Research 8 (4) 2022
    Citations: 3

  • Experience with nintedanib in severe pulmonary fibrosis associated with systemic sclerosis: a case series
    J Bordas-Martinez, AB Llanos-Gonzlez, R Jodar-Masanes, ...
    Open Respiratory Archives 3 (1), 100080 2021
    Citations: 3

  • Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF
    J Bordas-Martinez, N Salord, V Vicens-Zygmunt, J Carmezim, S Prez, ...
    Respiratory Research 25 (1), 247 2024
    Citations: 1

  • Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review
    J Bordas-Martinez, JR Miedema, BJ Mathot, L Seghers, RJH Galjaard, ...
    JHLT Open 3, 100054 2024
    Citations: 1

  • Pirfenidone in post-covid19 pulmonary fibrosis (FIBRO-COVID): Phase-II randomized clinical trial (NCT04607928)
    GB Peloche, B Del Ro, V Vicens-Zygmunt, C Valenzuela, R Laporta, ...
    European Respiratory Journal 62 (suppl 67) 2023
    Citations: 1

  • [Translated article] Multiple Solid Nodules at Post-COVID-19 Follow-Up After Mild Pneumonia
    J Bordas-Martinez, B Del Ro, M Molina-Molina
    Archivos de bronconeumologia 58 (4), T359 2022
    Citations: 1

  • N3 hilar sampling decision in the staging of mediastinal lung cancer
    J Bordas-Martinez, JL Vercher-Conejero, G Rodriguez-Gonzlez, ...
    ERJ Open Research 7 (3) 2021
    Citations: 1

  • Organizing pneumonia in a patient with hodgkin's lymphoma and large B cell lymphoma: a rare association
    J Bordas-Martinez, M Gasa, E Domingo-Domnech, V Vicens-Zygmunt
    Hematology, Transfusion and Cell Therapy 42 (2), 176-179 2020
    Citations: 1

  • Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases
    AB Llanos-Gonzlez, JB Martnez, GB Peloche, G Surez-Cuartn, ...
    European Respiratory Journal 54 (suppl 63) 2019
    Citations: 1